These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36173713)

  • 1. Generation of vessel co-option lung metastases mouse models for single-cell isolation of metastases-derived cells and endothelial cells.
    Cuypers A; Teuwen LA; Bridgeman VL; de Rooij LPMH; Eelen G; Dewerchin M; Cantelmo AR; Kalucka J; Bouché A; Vinckier S; Carton A; Manderveld A; Vermeulen PB; Reynolds AR; Carmeliet P
    STAR Protoc; 2022 Dec; 3(4):101691. PubMed ID: 36173713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.
    Bridgeman VL; Vermeulen PB; Foo S; Bilecz A; Daley F; Kostaras E; Nathan MR; Wan E; Frentzas S; Schweiger T; Hegedus B; Hoetzenecker K; Renyi-Vamos F; Kuczynski EA; Vasudev NS; Larkin J; Gore M; Dvorak HF; Paku S; Kerbel RS; Dome B; Reynolds AR
    J Pathol; 2017 Feb; 241(3):362-374. PubMed ID: 27859259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
    Coelho AL; Gomes MP; Catarino RJ; Rolfo C; Lopes AM; Medeiros RM; Araújo AM
    Oncotarget; 2017 Jun; 8(24):39795-39804. PubMed ID: 26950275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Inhibition of Vessel Co-Option as an Emerging Strategy for Cancer Therapy.
    Carrera-Aguado I; Marcos-Zazo L; Carrancio-Salán P; Guerra-Paes E; Sánchez-Juanes F; Muñoz-Félix JM
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment conditions that favor vessel co-option in colorectal cancer liver metastases: A theoretical model.
    Rada M; Lazaris A; Kapelanski-Lamoureux A; Mayer TZ; Metrakos P
    Semin Cancer Biol; 2021 Jun; 71():52-64. PubMed ID: 32920126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor vessel co-option probed by single-cell analysis.
    Teuwen LA; De Rooij LPMH; Cuypers A; Rohlenova K; Dumas SJ; García-Caballero M; Meta E; Amersfoort J; Taverna F; Becker LM; Veiga N; Cantelmo AR; Geldhof V; Conchinha NV; Kalucka J; Treps L; Conradi LC; Khan S; Karakach TK; Soenen S; Vinckier S; Schoonjans L; Eelen G; Van Laere S; Dewerchin M; Dirix L; Mazzone M; Luo Y; Vermeulen P; Carmeliet P
    Cell Rep; 2021 Jun; 35(11):109253. PubMed ID: 34133923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases.
    Frentzas S; Simoneau E; Bridgeman VL; Vermeulen PB; Foo S; Kostaras E; Nathan M; Wotherspoon A; Gao ZH; Shi Y; Van den Eynden G; Daley F; Peckitt C; Tan X; Salman A; Lazaris A; Gazinska P; Berg TJ; Eltahir Z; Ritsma L; Van Rheenen J; Khashper A; Brown G; Nystrom H; Sund M; Van Laere S; Loyer E; Dirix L; Cunningham D; Metrakos P; Reynolds AR
    Nat Med; 2016 Nov; 22(11):1294-1302. PubMed ID: 27748747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of tumour vascularization in experimental lung metastases.
    Szabo V; Bugyik E; Dezso K; Ecker N; Nagy P; Timar J; Tovari J; Laszlo V; Bridgeman VL; Wan E; Frentzas S; Vermeulen PB; Reynolds AR; Dome B; Paku S
    J Pathol; 2015 Feb; 235(3):384-96. PubMed ID: 25319725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protocols for endothelial cell isolation from mouse tissues: brain, choroid, lung, and muscle.
    Conchinha NV; Sokol L; Teuwen LA; Veys K; Dumas SJ; Meta E; García-Caballero M; Geldhof V; Chen R; Treps L; Borri M; de Zeeuw P; Falkenberg KD; Dubois C; Parys M; de Rooij LPMH; Rohlenova K; Goveia J; Schoonjans L; Dewerchin M; Eelen G; Li X; Kalucka J; Carmeliet P
    STAR Protoc; 2021 Sep; 2(3):100508. PubMed ID: 34585146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
    Donnem T; Hu J; Ferguson M; Adighibe O; Snell C; Harris AL; Gatter KC; Pezzella F
    Cancer Med; 2013 Aug; 2(4):427-36. PubMed ID: 24156015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution.
    Fleischer JR; Schmitt AM; Haas G; Xu X; Zeisberg EM; Bohnenberger H; Küffer S; Teuwen LA; Karras PJ; Beißbarth T; Bleckmann A; Planque M; Fendt SM; Vermeulen P; Ghadimi M; Kalucka J; De Oliveira T; Conradi LC
    Mol Cancer; 2023 Jan; 22(1):17. PubMed ID: 36691028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vessel co-option in cancer.
    Kuczynski EA; Vermeulen PB; Pezzella F; Kerbel RS; Reynolds AR
    Nat Rev Clin Oncol; 2019 Aug; 16(8):469-493. PubMed ID: 30816337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of vascularization in murine models of primary and metastatic tumor growth.
    Bugyik E; Renyi-Vamos F; Szabo V; Dezso K; Ecker N; Rokusz A; Nagy P; Dome B; Paku S
    Chin J Cancer; 2016 Feb; 35():19. PubMed ID: 26873579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing a mouse model of lung metastases using ultrasound-guided right heart ventricle injection.
    Labora A; Creech A; Lee H; Tabornal E; Radu C; Donahue T
    STAR Protoc; 2023 Dec; 4(4):102698. PubMed ID: 37925631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vessel co-option in glioblastoma: emerging insights and opportunities.
    Seano G; Jain RK
    Angiogenesis; 2020 Feb; 23(1):9-16. PubMed ID: 31679081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apelin inhibition prevents resistance and metastasis associated with anti-angiogenic therapy.
    Uribesalgo I; Hoffmann D; Zhang Y; Kavirayani A; Lazovic J; Berta J; Novatchkova M; Pai TP; Wimmer RA; László V; Schramek D; Karim R; Tortola L; Deswal S; Haas L; Zuber J; Szűcs M; Kuba K; Dome B; Cao Y; Haubner BJ; Penninger JM
    EMBO Mol Med; 2019 Aug; 11(8):e9266. PubMed ID: 31267692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.
    Drevs J; Hofmann I; Hugenschmidt H; Wittig C; Madjar H; Müller M; Wood J; Martiny-Baron G; Unger C; Marmé D
    Cancer Res; 2000 Sep; 60(17):4819-24. PubMed ID: 10987292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Models and molecular mechanisms of blood vessel co-option by cancer cells.
    Zhang Y; Wang S; Dudley AC
    Angiogenesis; 2020 Feb; 23(1):17-25. PubMed ID: 31628560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone marrow-derived, alternatively activated macrophages enhance solid tumor growth and lung metastasis of mammary carcinoma cells in a Balb/C mouse orthotopic model.
    Cho HJ; Jung JI; Lim DY; Kwon GT; Her S; Park JH; Park JH
    Breast Cancer Res; 2012 May; 14(3):R81. PubMed ID: 22616919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.